drugset / Trial / NCT03059017

In Vivo Investigation of Novel Nano-vesicles of Salbutamol Sulphate

NCT03059017

Phase 1 Completed 20 enrolled British University In Egypt
RandomizedParallel-groupOpen-labelTreatment

Summary

The relative bioavailability of different salbutamol sulphate inhaler formulations will be studied in healthy male subjects according to the ethical regulations of World Medical Association Declaration of Helsinki (1996) after the approval of the ethical committee, Faculty of Pharmacy, The British University in Egypt.

Timeline

Start
2017-02-05
Primary completion
2017-02-05
Completion
2017-02-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Salbutamol Unknown 0.8 mg Inhaled

Indications